Thai FDA drug registration follows a structured pathway from classification through dossier review to marketing authorization. Understanding the full process before you start saves months.
Drug registration in Thailand is administered by the Food and Drug Administration (Thai FDA, or อย.), a department of the Ministry of Public Health. The governing legislation is the Drug Act B.E. 2510 (1967) and its amendments, most significantly the amendment under B.E. 2562 (2019), which introduced 7-year marketing authorization validity, aligned post-market surveillance obligations with international standards, and clarified the licensing framework for overseas manufacturers.
Thai FDA's pharmaceutical division handles drug classification, dossier review, GMP accreditation for overseas manufacturers, import licensing, and post-approval compliance. A foreign manufacturer entering the Thai market must work through Thai FDA for every stage of the registration pathway, from the initial classification determination through to the marketing authorization and its ongoing maintenance.
Thailand classifies drugs into four categories that determine how they are sold and distributed: specially controlled drugs (narcotics and psychotropics), dangerous drugs (most prescription-only products), non-dangerous drugs (OTC products), and household remedy drugs (a defined list of common OTC items).
Separately, Thai FDA uses registration categories that determine the pathway and dossier requirements. These are not the same as the classification categories above.
A new chemical entity or new biological entity not previously registered in Thailand. Faces a 220-business-day review target and a mandatory minimum 2-year Safety Monitoring Program (SMP) before full registration is issued.
A generic product referencing a comparator that was first approved by Thai FDA after B.E. 2534 (1991). Requires a full bioequivalence study demonstrating the product performs comparably to the reference product. This is the most common pathway for foreign manufacturers today.
References a comparator approved by Thai FDA before B.E. 2534 (1991). Does not require a bioequivalence study. This pathway is largely historical.
A conditional registration pathway for products already approved by a recognized stringent regulatory authority (US FDA, EMA, and others). SMP registration is issued conditionally and requires a mandatory hospital-dispensing period before converting to full registration.
Confirm drug category and registration category. This determines the fee structure, dossier requirements, and whether a bioequivalence study is needed. A classification error affects every subsequent step.
A Thai-licensed entity with a valid establishment license must be appointed as the LAR. The LAR will be the named applicant and will hold the marketing authorization. The establishment license must be current and scoped to cover the relevant drug category.
Thai FDA must accredit every overseas manufacturing site before a marketing authorization can be issued. The LAR applies for GMP clearance on behalf of the manufacturer. GMP clearance is product-specific and valid for 3 years.
A limited importation pathway exists for importing samples for Thai FDA laboratory testing during review. This is a separate authorization from commercial importation and must be arranged before the dossier is submitted.
The registration dossier is prepared in ACTD format (not ICH CTD) and submitted through Thai FDA's e-Submission portal. Part I of the dossier must be in Thai. Formatting errors at this stage are the most common cause of screening failure.
Thai FDA screens for format and completeness before accepting the dossier for technical review. A dossier returned from screening must be corrected and resubmitted. The review clock does not start until the dossier passes screening.
Thai FDA's official target is 120 business days for generics and 220 business days for new drugs from the date of screening acceptance. Thai FDA may raise queries during review; response quality and speed affect the timeline directly.
For new drugs, Thai FDA requires physical product samples for laboratory verification. New drugs must also complete the Safety Monitoring Program before full registration is granted. During SMP, the drug may only be dispensed in hospitals.
Thai FDA issues the marketing authorization in the LAR's name. The MA is valid for 7 years under the Drug Act B.E. 2562 (2019) amendment and must be renewed within the 1-year window before expiration.
Thai FDA's 120-business-day generic review clock starts from the date the dossier is formally accepted at screening, not from the submission date. Screening itself takes additional time. A dossier returned from screening and resubmitted restarts the process.
For most foreign manufacturers with a well-prepared dossier, properly licensed LAR, and current GMP, the end-to-end timeline from first submission to marketing authorization runs 12 to 18 months for a generic. New drugs with a required SMP period face 3 years or more before full registration.
The marketing authorization is valid for 7 years. Renewal preparation should begin at least 18 months before the MA expiration date. An MA that lapses without a timely renewal forces the product off the market; there is no reinstatement shortcut, only a full new registration application.
Classification as generic instead of new generic (or vice versa) affects the dossier requirements and fee calculation. A misclassified application is rejected at screening or during review, requiring resubmission from the beginning.
An LAR whose establishment license has lapsed, is under renewal, or does not cover the relevant drug category cannot hold a marketing authorization. This is discovered at screening and forces a replacement or cure before the application can proceed.
GMP accreditation is product-specific. A certificate that has expired or does not cover the specific manufacturing steps used for the product will fail screening. Thai FDA may also check GMP validity during review.
The most common screening failure. Part I must be in Thai and must follow ACTD structure, not ICH CTD. Missing or incorrectly structured Thai-language labeling mock-ups and product information documents are the leading cause.
For new generic applications, the reference product used in the bioequivalence study must match what Thai FDA will accept as the comparator. Using an uncorrected comparator means the bioequivalence data is not usable, requiring a new study.
VeroPharma Group manages Thai FDA drug registration from classification strategy through marketing authorization and post-approval lifecycle. We hold the establishment licenses required to serve as LAR and IOR and manage GMP accreditation, ACTD dossier preparation, and Thai FDA correspondence in-house.
When a timeline is unrealistic or a classification is wrong, we say so before work begins. The most expensive mistakes in Thai drug registration happen in the first 60 days, before a dossier is ever submitted.